Clinical profile, management and outcome of patients diagnosed with Bronchiectasis enrolled in the Chronic Lung Disease Program in a tertiary pediatric hospital from 2021-2023
- Author:
Danielle P. Barretto
1
;
Jenni Rose D. Dimacal
1
Author Information
- Publication Type:Journal Article
- MeSH: Human; Male,Female; Infant newborn: First 28 days after birth; Infant: 1-23 months; Child Preschool: 2-5 yrs old; Child: 6-12 yrs old; Bronchiectasis; Patients; Tuberculosis; Infections
- From: The Philippine Children’s Medical Center Journal 2025;21(1):1-17
- CountryPhilippines
- Language:English
-
Abstract:
OBJECTIVE:This study described bronchiectasis profiles at the Philippine Children’s Medical Center (2021-2023).
MATERIALS AND METHODS:A retrospective chart review at PCMC analyzed the demographic profile, imaging, management and outcome of patients with bronchiectasis enrolled in the Chronic Lung Disease Program from 2021-2023.
Results:Twenty seven patients were included in this study. Most patients were diagnosed after the age of six and showed female predominance. The most common symptom at the time of diagnosis was chronic cough (81.5%) with pulmonary tuberculosis (51.9%) as the most common etiology. All patients were treated with cyclic azithromycin. Pseudomonas aeruginosa was the prevalent microorganism isolated in the sputum and tracheal aspirate samples of the patients (56.5%).
Conclusion:Patients with bronchiectasis were more commonly diagnosed in children past age of six with more prevalence in females. The most common symptom was chronic cough followed by fever, dyspnea and weight loss. Pulmonary tuberculosis and recurrent respiratory infections were noted to be the most common etiology with the left lower lobe most affected in HRCT. The most common phenotype seen was cystic, which is irreversible and a sign of progressive bronchiectasis, which may point to a late diagnosis. This emphasizes the need for physicians to have a high index of suspicion in patients with chronic or recurrent respiratory symptoms. All patients were treated with an oral macrolide with 25-31% of patients with decreased and/or absent symptoms. Pseudomonas aeruginosa was the prevalent microorganism isolated in the sputum and tracheal aspirate samples of the patients, which should be taken into account when treating for exacerbation. - Full text:2025090316112035744pcmc 21(1) Article 1.pdf
